Low-grade lymphoma: Beyond fludarabine-single therapy

참고문헌 (Reference)

1 Dreyling M, "Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in 1. patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)" 24 (24): 7502-, 2006

2 van Oers MH, "Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial" 108 : 3295-3301, 2006

3 Ferrario A, "Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)" 90 : 323-330, 2011

4 Horning SJ, "Natural history of and therapy for the indolent non-Hodgkin's lymphomas" 20 (20): 75-88, 1993

5 Zinzani PL, "Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma" 8 : 379-383, 1997

6 McLaughlin P, "Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma" 14 : 1262-1268, 1996

7 Lazzarino M, "Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma" 10 : 59-64, 1999

8 Eichhorst BF, "Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia" 107 : 885-891, 2006

9 Zinzani PL, "Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas" 11 : 363-365, 2000

10 Fowler N, "Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study" 29 : 3389-3395, 2011